| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 08/05/2003 | CA2087672C 1,5-benzodiazepine derivatives |
| 08/05/2003 | CA2075861C Dibenz[b,f][1,4]oxazepin-11(10h)-ones for multidrug resistance reversing agents |
| 08/01/2003 | CA2370396A1 Hepatitis c inhibitor tri-peptides |
| 07/31/2003 | WO2003062467A2 Tissue rejection |
| 07/31/2003 | WO2003062440A1 Xanthone derivative |
| 07/31/2003 | WO2003062414A2 Methods of obtaining isoform specific expression in mammalian cells |
| 07/31/2003 | WO2003062390A2 Compositions and methods for the modulation of sphingolipid metabolism and/or signaling |
| 07/31/2003 | WO2003062369A2 Expansion of renewable stem cell populations |
| 07/31/2003 | WO2003062278A1 MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR |
| 07/31/2003 | WO2003062277A1 Corticotropin releasing factor receptor 2 agonists |
| 07/31/2003 | WO2003062275A1 Glycoisoforms of adiponectin and uses thereof |
| 07/31/2003 | WO2003062269A2 Corticotropin releasing factor receptor 2 agonists |
| 07/31/2003 | WO2003062268A2 Corticotropin releasing factor receptor 2 agonists |
| 07/31/2003 | WO2003062265A2 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 07/31/2003 | WO2003062247A2 Phosphinic pseudo-peptide derivatives for selective inhibition of the active c-terminal site of angiotensin converting enzyme (i) (ace) |
| 07/31/2003 | WO2003062245A1 Fused bicyclic pyrimidine derivatives |
| 07/31/2003 | WO2003062243A1 Novel compounds as semaphorin inhibitors |
| 07/31/2003 | WO2003062240A1 Pteridine derivatives, method for the production thereof, and use thereof |
| 07/31/2003 | WO2003062238A1 Tricyclic 2-pyrimidone compounds useful as hiv reverse transcriptase inhibitors |
| 07/31/2003 | WO2003062236A1 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES |
| 07/31/2003 | WO2003062234A1 Quinoxaline compounds |
| 07/31/2003 | WO2003062233A1 2-acylaminothiazole derivative or salt thereof |
| 07/31/2003 | WO2003062228A1 Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection |
| 07/31/2003 | WO2003062227A1 Rho-kinase inhibitors |
| 07/31/2003 | WO2003062225A1 Pyrimidine derivatives as rho-kinase inhibitors |
| 07/31/2003 | WO2003062220A1 N-oxyde of n-phenyl-2-pyrimidine-amine derivatives |
| 07/31/2003 | WO2003062211A1 Pyrimidinone viral polymerase inhibitors |
| 07/31/2003 | WO2003062209A2 Substituted quinazolin-4-ylamine analogues as modulators of capsaicin |
| 07/31/2003 | WO2003062204A1 Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors |
| 07/31/2003 | WO2003062200A2 Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists |
| 07/31/2003 | WO2003062192A1 Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors |
| 07/31/2003 | WO2003062191A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 07/31/2003 | WO2003062189A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 07/31/2003 | WO2003061757A1 Transdermal/transmucosal preparations for electroporation |
| 07/31/2003 | WO2003061710A1 AGENT CONTROLLING THE APOPTOSIS INDUCTION BY p73 |
| 07/31/2003 | WO2003061704A2 Combination therapy for the treatment of bacterial infections |
| 07/31/2003 | WO2003061699A1 Remedies for allergic diseases |
| 07/31/2003 | WO2003061698A1 6-fluorobicyclo[3.1.0]hexane derivatives |
| 07/31/2003 | WO2003061697A1 Preventives/remedies for cancer |
| 07/31/2003 | WO2003061691A1 Orodispersible pharmaceutical composition comprising perindopril |
| 07/31/2003 | WO2003061689A1 Thrombin derived peptides for promoting cardiac tissue repair |
| 07/31/2003 | WO2003061688A1 Novel analgesics |
| 07/31/2003 | WO2003061682A1 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus |
| 07/31/2003 | WO2003061667A1 Pharmaceutically acceptable phosphate-glycerol carrying bodies |
| 07/31/2003 | WO2003061666A1 Phospholipid bodies and use thereof in the treatment of inflammatory and autoimmune diseases |
| 07/31/2003 | WO2003061663A1 Use of benzothiazepines having activity as inhibitors of ileal bile acid transport for reducing cholesterololemia |
| 07/31/2003 | WO2003061660A1 Melanocortin receptor agonists |
| 07/31/2003 | WO2003061659A1 Treating stress response with chemokine receptor ccr5 modulators |
| 07/31/2003 | WO2003061658A1 Sigma receptor binder containing indanone derivative |
| 07/31/2003 | WO2003061656A1 Pharmaceutical composition and method for treating disorders of the central nervous system |
| 07/31/2003 | WO2003061655A1 2-aminothiazole allosteric enhancers of a1 adenosine receptors |
| 07/31/2003 | WO2003061653A1 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
| 07/31/2003 | WO2003061652A1 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
| 07/31/2003 | WO2003061648A1 Use of cholinesterase antagonists to treat insulin resistance |
| 07/31/2003 | WO2003061645A1 Pharmaceutical use of cox-2 inhibitors in angiogenesis-mediated ocular disorders |
| 07/31/2003 | WO2003061642A1 Use of ambroxol in the treatment of chronic pains, cerebral excitotoxicity-related disorders and cardiac arrhythmias |
| 07/31/2003 | WO2003061634A1 Sustained release pharmaceutical composition |
| 07/31/2003 | WO2003061632A1 Method of treatment of a patient requiring analgesia |
| 07/31/2003 | WO2003061626A1 Polymeric gel system for the controlled delivery of codrugs |
| 07/31/2003 | WO2003061620A2 Peptide-carrying bodies for immune response |
| 07/31/2003 | WO2003061604A2 Novel alkyl/aryl hydroxy or keto thiepines. |
| 07/31/2003 | WO2003061584A2 Novel substituted benzimidazole dosage forms and method of using same |
| 07/31/2003 | WO2003061580A2 Alteration of rab38 function to modulate mammalian pigmentation |
| 07/31/2003 | WO2003061573A2 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo |
| 07/31/2003 | WO2003061571A2 Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein |
| 07/31/2003 | WO2003061566A2 Anti-cancer combination and use thereof |
| 07/31/2003 | WO2003061560A2 Replication competent dual-ad vectors for vaccine and immunotherapy applications |
| 07/31/2003 | WO2003061553A2 An extract of acanthopanax koreanum for the treatment or prevention of hepatitis or the liver protective drug |
| 07/31/2003 | WO2003057698A3 Spiroazacyclic compounds as monoamine receptor modulators |
| 07/31/2003 | WO2003041649A3 Cyanoalkylamino derivatives as protease inhibitors |
| 07/31/2003 | WO2003039460A3 Mitotic kinesin inhibitors |
| 07/31/2003 | WO2003037269A3 Di-, tri,- and tetra-peptides having antiangiogenic activity |
| 07/31/2003 | WO2003035679A3 Molecules |
| 07/31/2003 | WO2003027246A3 Antagonists |
| 07/31/2003 | WO2003027061A3 Muscarinic agonists |
| 07/31/2003 | WO2003020702A9 Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain |
| 07/31/2003 | WO2003018545B1 24-sulfur-substituted analogs of 1α,25-dihydroxy vitamin d¿3? |
| 07/31/2003 | WO2003014702A3 Uses of mammalian cytokine; related reagents |
| 07/31/2003 | WO2003010243A3 Multipotent stem cells from peripheral tissues and uses thereof |
| 07/31/2003 | WO2003008630A3 Methods of profiling gene expression, protein or metabolite levels |
| 07/31/2003 | WO2003008578A3 Reagents and methods for identifying gene targets for treating cancer |
| 07/31/2003 | WO2003006607A3 Inhibition of apoptosis process and improvement of cell performance |
| 07/31/2003 | WO2003006016A3 Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury |
| 07/31/2003 | WO2003004607A3 Aggrecanase molecules |
| 07/31/2003 | WO2003002596A3 Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders |
| 07/31/2003 | WO2003000023A3 Method of treating hyperproliferative diseases using active vitamin d analogues |
| 07/31/2003 | WO2002101005A3 A g-protein coupled receptor and uses therefor |
| 07/31/2003 | WO2002100408A3 Treating neuropathic/inflammatory pain by targeting a composition (e.g. zd7288) to hcn pacemaker channels |
| 07/31/2003 | WO2002099042A3 Cads as modifiers of the p53 pathway and methods of use |
| 07/31/2003 | WO2002098453A3 Orally administering parathyroid hormone and calcitonin |
| 07/31/2003 | WO2002094767A3 Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors |
| 07/31/2003 | WO2002094202B1 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 07/31/2003 | WO2002092065A3 Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors |
| 07/31/2003 | WO2002086123A3 A human g-protein coupled receptor, hgprbmy11, expressed highly in heart and variants thereof |
| 07/31/2003 | WO2002068421A3 Tricyclic compounds and their analogs as inhibitors of cytokine signaling |
| 07/31/2003 | WO2002064627A3 Crystallization of igf-1 |
| 07/31/2003 | WO2002062762A3 Potassium channel openers |
| 07/31/2003 | WO2002060892A8 Ethanolates of sodium-hydrogen exchanger type-1 inhibitor |
| 07/31/2003 | WO2002040471A9 Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| 07/31/2003 | WO2002030514A3 Insulin receptor activators for the treatment of metabolic disorders in humans resulting from treatment of hiv infection with hiv protease inhibitors |